Development
Cytokinetics, Incorporated
CYTK
$35.14
-$1.02-2.82%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -35.30% | -86.69% | -149.91% | -67.20% | -80.65% |
| Total Depreciation and Amortization | 104.54% | 47.55% | 71.63% | 105.23% | 155.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -10.52% | -0.74% | 55.57% | 60.26% | 74.56% |
| Change in Net Operating Assets | 112.50% | 66.99% | 77.97% | -292.99% | -392.15% |
| Cash from Operations | -38.33% | -78.20% | -112.32% | -182.51% | -110.15% |
| Capital Expenditure | 87.51% | 82.44% | 69.78% | 75.00% | 76.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 195.96% | 262.47% | 96.13% | 86.82% | -153.58% |
| Cash from Investing | 191.27% | 243.38% | 90.34% | 84.35% | -77.38% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | 99.55% | 99.61% | -193.93% | -195.68% | -- |
| Issuance of Common Stock | 941.40% | -54.44% | -94.27% | -94.82% | -94.59% |
| Repurchase of Common Stock | -9.53% | 25.15% | 25.15% | 25.15% | -115.82% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -71.19% | -48.09% | -82.12% | -82.49% | -- |
| Cash from Financing | -57.12% | -83.71% | -0.11% | -0.55% | 61.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 201.61% | -139.37% | -143.59% | -117.23% | -253.24% |